[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"apraxia-of-speech\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:apraxia-of-speech":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,42,69,89,114,143,174],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100320466","using-tdcs-in-speech-based-stroke-rehabilitation-100320466",false,"NCT03452202","Using tDCS in Speech-based Stroke Rehabilitation","Inclusion Criteria:\n\n* Right-handed\n* Monolingual (English)\n* Single left-hemisphere CVA\n* A minimum of six months post-stroke\n* Clinical diagnosis of apraxia of speech\n* Normal speech perception\n* Passing score on the hearing screening.\n\nExclusion Criteria:\n\n* Diagnosis of laryngeal voice disorder\n* Dysarthria\n* History of speech impairment prior to CVA\n* Presence of potential tDCS risk factors: damaged skin at site of stimulation;\n* Presence of electrically or magnetically activated implant (including pacemaker);\n* metal in any part of their body;\n* history of medication-resistant epilepsy in the family;\n* past history of seizures or unexplained spells of loss of consciousness.","ALL","18 Years","99 Years",{"count":19,"type":20},24,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to determine whether the effect of treatment for acquired speech impairment can be enhanced by combining effective behavioral treatment with non-invasive brain stimulation. Transcranial direct current stimulation (tDCS), which delivers low-intensity current to the scalp, and is a safe and well-tolerated approach that poses a non-significant risk to participants. tDCS provides low intensity neural stimulation which has been shown to facilitate motor learning in other domains of stroke rehabilitation such as arm motor learning but the potential to enhance speech motor learning has not been explored. This will be examined with a series of single-case experimental designs.",[26],"Apraxia of Speech",[28],"Stroke","RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":33},"2019-01-11",{"date":37,"type":20},"2027-04-30",{"name":39,"class":40},"NYU Langone Health","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":68},"100309796","the-neurobiology-of-two-distinct-types-of-progressive-apraxia-of-speech-100309796","NCT03313011","The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech","SLD4T","Inclusion Criteria:\n\n1. All enrolled patients must be over the age of 18, speak English as their primary language, and have an informant who can provide an independent evaluation of functioning.\n2. Each new patient must present with a chief complaint of progressive impairment of speech and must have evidence of AOS documented by a speech-language pathologist during routine clinical evaluation.\n3. At study entry, all patients must have speech sufficiently intelligible for a confident diagnosis of AOS, dysarthria, and\u002For aphasia, and for acoustic analysis.\n\nExclusion Criteria:\n\n1. Any patient whose speech is not intelligible enough for confident speech-language diagnosis will be excluded from the study.\n2. All patients with concurrent illnesses that could account for speech deficits (e.g., traumatic brain injury, strokes, developmental syndromes), and patients meeting criteria for another neurodegenerative disease (e.g., Alzheimer's type dementia57), will be excluded.\n3. Patients with aphasia or dysarthria who do not have PAOS, or whose aphasia or dysarthria at study entry is more severe than PAOS, will be excluded.\n4. All women who are pregnant, or post-partum and breast-feeding, will be excluded as they are unable to undergo the required imaging. All women who can become pregnant must have a pregnancy test no more than 48 hours before the DaTscan.\n5. Patients will also be excluded if MRI is contraindicated (e.g., metal in head, cardiac pace maker), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy).\n6. Patients will be excluded if they do not have an informant, or do not consent to the research.",{"count":50,"type":20},47,"OBSERVATIONAL","The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.",[26,54,55,56],"Non-fluent Aphasia","Primary Progressive Aphasia","Primary Progressive Nonfluent Aphasia",[58],"apraxia of speech","2026-04-27",{"date":61,"type":33},"2026-05-01",{"date":63,"type":33},"2017-08-01",{"date":65,"type":20},"2027-07",{"name":67,"class":40},"Mayo Clinic",1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":75,"enrollmentInfo":4,"targetDuration":4,"studyType":76,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":87,"locationsCount":41},"100310906","expanded-access-protocol-umbilical-cord-blood-infusions-for-children-with-brain-injuries-100310906","NCT03327467","Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries","Under this protocol, participants may be eligible for infusion of autologous, sibling, and\u002For unrelated donor CB cells (Duke only). Some eligibility criteria vary based on CB source. For all participants, eligibility is predicated on the availability of a qualifying CB unit To be eligible, patients must:\n\nInclusion Criteria:\n\n1. Age at Consent:\n\n   1. Autologous: 0-26 years\n   2. Sibling: 6 months - 26 years\n   3. Unrelated Donor (Duke only): 6 months - 26 years\n2. Diagnosis\n\n   1. Autologous and Sibling: Cerebral palsy, Hypoxic brain injury, Stroke, Hydrocephalus, Apraxia (without autism), Other brain injury\n   2. Unrelated Donor (Duke only): Motor impairment secondary to: Hypoxic brain injury, Periventricular leukomalacia, Stroke\u002Fbleed, Congenital hydrocephalus\n3. Functional Status:\n\n   1. Autologous and Sibling: See exclusion criteria\n   2. Unrelated Donor (Duke only): GMFCS level I-IV (age ≥2)\n4. No clinically significant abnormalities in blood counts and basic chemistries for age.\n5. Absolute Lymphocyte Count:\n\n   * 1200 for African American participants\n   * 1500 for all other participants\n6. Availability of a qualified autologous or Sibling CB Unit\n\n   1. Autologous or Sibling: available\n   2. Unrelated Donor (Duke only): N\u002FA\n7. Written informed consent obtained from the parent or legal guardian.\n\nExclusion Criteria:\n\n1. Documented HIV or Hepatitis or other disease transmittable through the blood.\n2. A cord blood unit that fails to meet specifications\n3. Refusal of consent\n4. Uncontrolled seizure disorder\n5. Uncontrolled infection\n6. Diagnosed with a genetic or metabolic disorder related to the neurologic condition\n7. History of an immune deficiency\n8. History of treatment with chemo or immunosuppressive therapy\n9. History of previous allogeneic cell therapy outside of participation in a Duke clinical trial\n10. Need for mechanical ventilation or chronic O2 support\n11. Unstable airway\n12. Eligible for an active clinical trial of cellular therapy at Duke. If previously enrolled on another Duke cell therapy protocol the participant may still be considered for enrollment on this study after the follow-up period for the clinical trial is completed.\n13. Cerebral palsy secondary to infection, congenital or otherwise, without another known cause\n14. Pregnant or breastfeeding\n15. Treated with autologous cellular therapy through a non-intravenous route (ie. intrathecally) within one year prior to enrollment.\n\nUmbilical Cord Blood Criteria\n\nParticipant enrollment is dependent on the availability of a banked unit of autologous or sibling CB that has been stored at a private or public bank, or, if enrolling at Duke, availability of a publicly banked unrelated donor unit. Units must meet the following criteria:\n\nPrecryopreservation:\n\n1. TNCC ≥2x107\u002Fkg\n2. Sterility cultures performed and negative\n3. Viability ≥70%\n4. At least haploidentical HLA match for sibling units and at least a 4\u002F6 HLA match for unrelated donor units\n5. Donor screening testing performed and negative\n\nCBU Test sample\n\n1. Segment or test vial available\n2. Identity confirmed via HLA typing of test sample and donor\n3. Viability testing recommended, but not required","26 Years","EXPANDED_ACCESS","This protocol is designed to enable access to intravenous infusions of banked umbilical cord blood (CB), that is thawed and not more than minimally manipulated, for children with various brain disorders. Children with cerebral palsy, congenital hydrocephalus, apraxia, stroke, hypoxic brain injury and related conditions will be eligible if they have normal immune function and do not qualify for, have previously participated in, or are unable to participate in an active cell therapy clinical trial at Duke Medicine. For the purpose of this protocol the term children refers to patients less than 26 years of age. Cord blood is administered as a cellular infusion without prior treatment with chemotherapy or immunosuppression. The mechanism of action is through paracrine signaling of cord blood monocytes inducing endogenous cells to repair existing damage.",[79,80,26,81,82],"Cerebral Palsy","Hydrocephalus","Hypoxia Ischemia, Cerebral","Drowning; Anoxia","AVAILABLE","2026-01-22",{"date":86,"type":33},"2026-01-23",{"name":88,"class":40},"Joanne Kurtzberg, MD",{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":21,"phases":97,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":68},"100195328","phase-4-longitudinal-multi-modality-imaging-in-progressive-apraxia-of-speech-100195328","NCT01818661","Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech","Inclusion Criteria:\n\n* We will study subjects that fulfill clinical inclusion criteria for neurodegenerative AOS that have been seen and diagnosed at Mayo Clinic\n\nExclusion Criteria:\n\n* Subjects with concurrent illnesses that could account for speech and language deficits, such as traumatic brain injury, strokes or developmental syndromes will be excluded.\n* Women that are pregnant or post-partum and breast-feeding will be excluded. All women who can become pregnant must have a pregnancy test no more than 48 hours before the PET scan.\n* Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy).\n* Subjects will also be excluded if they do not have an informant, or do not consent to research.",{"count":96,"type":20},50,[98],"PHASE4","The study is designed to determine the relationship between structural and functional changes in the brain on imaging and progression of speech and language, neurological and neuropsychological features in patients with neurodegenerative apraxia of speech (AOS).",[101,54,26,102,55],"PPA","Primary Progressive Non-fluent Aphasia",[58,104,105],"non-fluent aphasia","aphasia","2025-11-10",{"date":108,"type":33},"2025-11-12",{"date":110,"type":33},"2018-07-01",{"date":112,"type":20},"2028-06",{"name":67,"class":40},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":21,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":68},"100551980","motor-imagery-for-treatment-enhancement-and-efficacy-in-persons-with-apraxia-of-speech-100551980","NCT06467136","Motor Imagery for Treatment Enhancement and Efficacy in Persons With Apraxia of Speech","Motor Imagery for Treatment Enhancement and Efficacy (MI-TEE) in Persons With Apraxia of Speech","MI-TEE","Inclusion Criteria:\n\n* Between the ages of 18 and 90 yrs. old\n* At least 6 months post left hemisphere stroke\n* Demonstrate AOS\n* Speak English as their primary language\n* Pass a hearing screening at 35 dB HL at 500, 1K, and 2K Hz for at least one ear\n* Normal or corrected to normal visual acuity\n\nExclusion Criteria:\n\n* Unable to follow two-step commands and greater than moderate aphasia\n* Moderate - severe dysarthria\n* Untreated depression or other psychiatric illness\n* Degenerative neurological illnesses\n* Less than 3 on the MIQ-RS77\n* Less than a 4 on 3\u002F5 domains on the FACETS\n* Less than a 23 on the Raven's Coloured Progressive Matrices\n* Receive other speech therapy while participating in the study","90 Years",{"count":124,"type":20},18,[23],"Treatment of post-stroke apraxia of speech (AOS) requires frequent and ongoing practice with a speech-language pathologist to facilitate lasting behavioral change, which is costly and, therefore, inaccessible to many patients. Thus, there is a critical need to identify novel, cost-effective ways to supplement speech therapy to increase opportunities for practice and optimize treatment outcomes. Our long-term goal is to develop an effective, home-practice, computer-based, motor imagery protocol Motor Imagery for Treatment Enhancement and Efficacy (MI-TEE) which will serve as an adjunct to routine speech therapy to optimize treatment response in persons with AOS. The overall objectives of this application are to (i) evaluate the acceptability and feasibility of MI-TEE as a home practice program and (ii) determine the efficacy of MI-TEE with speech therapy, compared to speech therapy alone, in improving speech production in people with AOS. Our central hypothesis is that MI-TEE will be an accessible, feasible, and efficacious adjunct to speech therapy. To attain our objectives, the following specific aims will be pursued using two single-subject experimental designs with multiple baselines across participants (n=18): 1) Evaluate the acceptability and feasibility of MI-TEE as an adjunct to speech therapy for the rehabilitation of AOS; and 2) Compare the efficacy of adjunctive MI-TEE plus standard speech therapy to standard speech therapy alone. Under the first aim, observational data, surveys, and semi-structured interviews will be employed to assess the acceptability (perceived satisfaction, appropriateness, and intent to continue use) and feasibility (recruitment, retention, and intervention adherence rates) of MI-TEE. For the second aim, accuracy of articulation for trained words and untrained words (generalization) will be measured pre-treatment, repeatedly during the treatment phase, and post-treatment. Improvements in speech accuracy will be documented using a binary scoring system (correct\u002Fincorrect). Multilevel analyses will be used to address rate of acquisition, overall change, and response variation across participants.",[128,26],"Apraxia, Oral",[130,131,132,133],"Treatment of Apraxia of Speech","Home Practice for Apraxia of Speech","AOS","Apraxia of speech","2025-06-22",{"date":136,"type":33},"2025-06-26",{"date":138,"type":33},"2023-12-11",{"date":140,"type":20},"2026-07-31",{"name":142,"class":40},"University of Central Florida",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":15,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":21,"phases":154,"briefSummary":155,"conditions":156,"keywords":161,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":68},"100555444","measuring-aided-language-development-100555444","NCT06512168","Measuring Aided Language Development","MALD","Inclusion Criteria:\n\n* Clinical Identification of Down Syndrome or Cerebral Palsy + Significant Speech Impairment\n* Must Speak English as a Primary Language\n* Must Be Able to Express At Least 25 Words (using any communication mode)\n* Must Be Able to Accurately Select Picture Symbols on iPad Communication App with at Least 50% Accuracy\n* Vision and Hearing within Functional Limits or Corrected to be within Functional Limits for Study Activities\n\nExclusion Criteria:\n\n* Clinical Diagnosis of Autism or Social Communication Disorder\n* Primary Language Spoken is A Language Other than English","42 Months","60 Months",{"count":153,"type":20},60,[23],"The focus of the current study is to systematically investigate the psychometric properties of a range of aided language measures, which are based on the Graphic Symbol Utterance and Sentence Development Framework (Binger \\& Kent-Walsh).",[157,79,26,158,159,160],"Down Syndrome","Speech Sound Disorder","Speech Disorders in Children","Speech and Language Disorder",[162,163,164,165],"Augmentative and Alternative Communication","Complex Communication Needs","Assistive Technology","AAC","2025-05-13",{"date":168,"type":33},"2025-05-16",{"date":170,"type":33},"2025-04-01",{"date":172,"type":20},"2028-03-31",{"name":142,"class":40},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":181,"enrollmentInfo":182,"targetDuration":4,"studyType":21,"phases":184,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":68},"100408897","changes-in-neuroplasticity-following-intensive-rehabilitation-of-aphasia-andor-apraxia-of-speech-100408897","NCT04604444","Changes in Neuroplasticity Following Intensive Rehabilitation of Aphasia and\u002For Apraxia of Speech","Evaluating the Effects of Intensive Speech and Language Rehabilitation Regarding Neuroplasticity, Speech, Language, Communication Skills and Quality of Life for People With Acquired Aphasia and\u002For Apraxia of Speech in the Chronic Phase","Inclusion Criteria:\n\n* Aphasia 7 months post stroke diagnosed by SLP\n* Apraxia of Speech 7 months post stroke diagnosed by SLP\n\nExclusion Criteria:\n\n* Dementia\n* Severe loss of sight\n* Severe loss of hearing\n* Metal implants (preventing fMRI)\n* Claustrophobia (preventing fMRI)","75 Years",{"count":183,"type":20},30,[23],"The present study aims to investigate the short- and long-term effects of two weeks of intensive speech-language pathology intervention with additional physiotherapy, on aphasia and apraxia of speech (AOS) and their neural correlates in thirty persons with chronic stroke. Changes are studied following intensive treatment of aphasia and AOS with standardised speech-language testing and testing of communication and with voxel-based morphometry (VBM) analysis and resting state functional connectivity (rsFC).",[187,26,188],"Aphasia","Dysarthria",[190,191,192],"Intensive Aphasia Rehabilitation","Intensive Apraxia of Speech Rehabilitation","Neuroplasticity","2024-10-30",{"date":195,"type":33},"2024-10-31",{"date":197,"type":33},"2017-02-02",{"date":199,"type":20},"2027-12-31",{"name":201,"class":40},"Karolinska Institutet"]